Research Programme Laboratory Sciences Defining The Transcriptional And Epigenetic Rewiring That Accompanies Malignant Transformation Of Low Grade Glioma. Brain Tumour Charity. Principal Applicant. £90,000. 2016-17. Building infrastructure for brain cancer research: from genome editing to drug discovery with new patient-derived cellular models. Cancer Research UK. Co-applicant. (Principal applicant, Dr Steve Pollard, Edinburgh) £3.7 million. 2016-2021 Chromatin proteins as drug targets for glioblastoma. Brain Tumour Charity. Brain Tumour Charity. Co applicant. (Principal Applicant Dr Steve Pollard, Edinburgh) £1,481,356. 2016-2021 Palladium-activated prodrug therapy: a novel focal therapy for localised cancers of unmet need. ESPRC. Co-applicant. (Principal applicant Dr Asier Unciti-Broceta, Edinburgh) £1,074,212. 2016-2021. Focal Chemotherapy of Glioma by Activation of Anticancer Drugs via Palladium-Functionalized Implants CRUK Pioneer award. Principal applicant. £173,609.83. 2016-2018. Nucleosome repositioning as a mechanism for cell memory in cancer Transitions. Wellcome Trust. Co-applicant (Principal applicant Vladimir Teif, Exeter) £85,432.00. 2015-2016 Somatic retrotransposition drives neoplastic mutagenesis in glioblastoma mutiforme Co-applicant. (Principal applicant Professor Geoff Faulkner, Mater Medical Research Institute Ltd) Funder NHMRC Grant 2012-2015 Clinical Sciences Understanding the diagnostic pathway for brain tumours in adults and its potential impact on clinical care and outcomes. The Brain Tumour Charity. Principal applicant. £266, 670. June 2015-2017. Novel Sample Preparation for Improved Circulating Tumour DNA Analysis. Chief Scientists Office. Co-applicant. £220,883. May 2015-2018 A randomised, double blind, placebo-controlled trial of a two-week course of dexamethasone for adult patients with a symptomatic Chronic Subdural Haematoma (Dex-CSDH trial). NIHR Heath Technology Assessment Programme (Call 13/15). £1,210,656.05. Co-applicant. September 2014-2019 Treatment of poor-grade subarachnoid haemorrhage trial 2 (TOPSAT2). NIHR Efficacy and Mechanism Evaluation. Co-applicant. £1,255,450.00. This article was published on 2024-09-23
